Combining stereotactic radiotherapy with immunotherapy and chemotherapy for treating triple-negative breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial is an open-label, multicenter, randomized study involving 136 patients with stage II-III triple-negative breast cancer. Participants will be assigned to either an experimental group receiving adebrelimab combined with stereotactic radiotherapy followed by chemotherapy, or a control group receiving adebrelimab with chemotherapy alone. The aim is to evaluate the effectiveness of this combination treatment in improving patient outcomes compared to standard chemotherapy. The study focuses on treatment-naïve female patients aged 18 to 75 with confirmed triple-negative breast cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Treatment-naïve breast cancer female patients aged ≥ 18 years and ≤ 75 years;
* Histopathologically confirmed early or locally advanced triple-negative invasive breast cancer according to the latest ASCO/CAP guidelines, meeting the following conditions: (1) pathological type is triple-negative, specifically: ER negative: IHC \< 1%, PR negative: IHC \< 1%, HER2 negative: IHC 0/1 + or IHC2 + but ISH negative;
* Clinical stage II-III invasive breast cancer with measurable lesions according to RECIST 1.1;
* ECOG score 0-1;
* Able to tolerate preoperative and postoperative adjuvant radiotherapy after assessment by a radiologist;
* Appropriate level of organ function
* Patients voluntarily participate in and sign the informed consent form, are expected to have good compliance and cooperate with the study according to the requirements of the protocol.

Exclusion Criteria:

* Patients with metastatic breast cancer or bilateral breast cancer;
* Patients with inflammatory breast cancer or occult breast cancer;
* Patients received any anti-tumor therapy within 12 months before signing the informed consent form, including chemotherapy, targeted therapy, radiotherapy, endocrine therapy, immunotherapy, biological therapy or tumor embolization;
* Patients previously received PD-1/PD-L1 antibody, CTLA-4 antibody, or other treatments against PD-1/PD-L1 inhibitors;
* Female patients who are pregnant and lactating, female patients who are fertile and have a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial.
* Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia, and the subject has a known history of psychotropic drug abuse, alcoholism ;
* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS); positive hepatitis B surface antigen (HBsAg) test, or positive hepatitis B core antibody (HBcAb) test followed by positive HBV-DNA test (HBV-DNA test was performed only in patients with negative HBsAg test and positive HBcAb test); positive hepatitis C virus (HCV) antibody test followed by positive HCV-RNA test (HCV-RNA test was performed only in patients with positive HCV antibody test)
* Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.

Where it's running

• Shengjing Hospital of China Medical University
  Shenyang, Liaoning, China Recruiting

Study contacts

• Study coordinator: Caigang Liu, Dr.
• Email: liucg@sj-hospital.org
• Phone: 18940254967

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VSV-02 for advanced solid tumors

  This treatment will try VSV-02 given into a vein and directly into tumors to see if it helps people with advanced solid tumors who have limited treatment options.

  Recruiting Phase 1 The First Affiliated Hospital of Xinxiang Medical College · Xinxiang, Henan · NCT07260591

• Using Biolosion with standard therapy to treat triple-negative breast cancer

  This study is testing if adding a new oral probiotic called Biolosion to standard treatment can help women with locally advanced triple-negative breast cancer have better outcomes.

  Recruiting Phase 2 Sun Yat-sen University · Lanzhou, Gansu and 4 other locations · NCT06768931

• Adebelizumab with chemotherapy given with radiotherapy at the same time versus after radiotherapy for extensive-stage small cell lung cancer

  This study tests whether adding adebelizumab to chemo and radiotherapy works better when given at the same time as radiotherapy compared to after radiotherapy in adults with extensive-stage SCLC.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06768307

• Treatment for advanced esophageal squamous cell carcinoma using adebrelimab and chemotherapy

  This study is testing if a new immunotherapy called adebrelimab, with or without chemotherapy, can help people with advanced esophageal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06510660

• Combining targeted therapies for solid tumors using CDK4/6 inhibitors and anti-VEGF agents

  This study is testing if combining two cancer treatments, Palbociclib and Bevacizumab, can help people with solid tumors like colorectal, breast, and ovarian cancers feel better and respond better to treatment.

  Recruiting at 2 sites Phase 1 Lebanese University · Tripoli, North Lebanon and 1 other locations · NCT06307249

• Combination treatment for advanced HR+/HER2- breast cancer

  This study is testing a new combination of treatments for people with advanced HR+/HER2- breast cancer to see if it can help them feel better after their previous treatments didn't work.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06149130

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.